UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates at 12 months


...

Related Keywords

Israel ,Kaplan Meier ,Urogen Rtgel ,William Huang ,Mark Schoenberg ,Nasdaq ,Urogen Pharma Ltd ,Grossman School Of Medicine ,Drug Administration ,Urogen Pharma ,Urologic Oncologist ,Vice Chair ,Disease Free Survival ,Chief Medical Officer ,New Drug Application ,Non Muscle Invasive Bladder Cancer ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,